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Background: The purpose of this study was to evaluate the brachial plexus (BP) dose of postmastectomy
radiotherapy (PMRT) to the ipsilateral supraclavicular (ISCL) area, and report the characteristics of radiation-induced
brachial plexus neuropathy (RIBPN).
Methods: The BP dose of 31 patients who received adjuvant PMRT to the ISCL area and chest wall using
three-dimensional conformal radiotherapy (3DCRT) and the records of 3 patients with RIBPN were retrospectively
analyzed based on the standardized Radiation Therapy Oncology Group-endorsed guidelines. The total dose to the
ISCL area and chest wall was 50 Gy in 25 fractions.
Results: Patients with a higher number of removed lymph nodes (RLNs) had a higher risk of RIBPN (hazard ratio
[HR]: 1.189, 95% confidence interval [CI]: 1.005-1.406, p = 0.044). In 31 patients treated with 3DCRT, the mean dose
to the BP without irradiation to the ISCL area was significantly less than that with irradiation to the ISCL area
(0.97 ± 0.20 vs. 44.39 ± 4.13 Gy, t = 136.75, p <0.001). In the 3DCRT plans with irradiation to the ISCL area and chest
wall, the maximum dose to the BP was negatively correlated with age (r = −0.40, p = 0.026), body mass index (BMI)
(r = −0.44, p = 0.014), and body weight (r = −0.45, p = 0.011). Symptoms of the 3 patients with RIBPN occurred 37–65
months after radiotherapy, and included progressive upper extremity numbness, pain, and motor disturbance. After
treatment, 1 patient was stable, and the other 2 patients’ symptoms worsened.
Conclusions: The incidence of RIBPN was higher in patients with a higher number of RLNs after PMRT. The dose to
the BP is primarily from irradiation of the ISCL area, and is higher in slim and young patients. Prevention should be
the main focus of managing RIBPN, and the BP should be considered an organ-at-risk when designing a radiotherapy
plan for the ISCL area.
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Clinical trials have confirmed that adjuvant postmastec-
tomy radiotherapy (PMRT) can improve the locoregional
control rate (LCR) and survival rate of patients with lo-
cally advanced breast cancer, especially with axillary
lymph node metastasis [1-3]. The incidence of recurrence
in ipsilateral supraclavicular or infraclavicular fossa with-
out PMRT is 4%-8%, when patients had locoregional
recurrence, supraclavicular or infraclavicular fossa was in-
volved in 23%-43% of failures [4-7]. Therefore, the guide-
lines of the National Comprehensive Cancer Network
(NCCN) and the German Society of Radiation Oncology
(DEGRO) recommend irradiation to chest wall (breast)
and the ipsilateral supraclavicular (ISCL) area for pa-
tients with locally advanced breast cancer [8,9]. Because
of the curative intent of breast cancer surgery, attention
should be given to late-stage injury after PMRT. It has
been reported 14%-20% breast cancer patients developed
radiation-induced brachial plexus neuropathy (RIBPN)
after radiotherapy in recent years [10,11].
The brachial plexus (BP) is formed by the last 4 cer-
vical nerves (C5-C8) and the 1st thoracic nerve (T1).
RIBPN symptoms include upper extremity numbness,
pain, weakness, and motor disturbance. RIBPN is slowly
progressive and often leads to permanent disability and
seriously affects the quality of life.
The risk of RIBPN is interested in head and neck can-
cer treated with high-dose radiation therapy and lung
cancer treated with stereotactic body radiotherapy [12,13].
However, because the conventional fractionated irradi-
ation method is more commonly used in PMRT, BP injury
should be different from that occurring with stereotactic
body radiation therapy. At present, the BP is not always
regarded as an organ-at-risk (OAR) in the optimization
and restriction of plans designed for the radiotherapy of
breast cancer.
Thus, the purpose of this study was to perform a
retrospective analysis of the radiation dose to the BP in
3DCRT plans with PMRT to the ISCL area and chest
wall. We further investigated the dosimetric features of
the BP in radiotherapy, and the potential correlation
with physical features. Lastly, we reported 3 patients
with RIBPN after PMRT.
Materials and methods
Patients
We retrospectively analyzed the 3DCRT plans of 31
breast cancer patients who received PMRT to the ISCL
area and chest wall between January 2007 and December
2007 at Sun Yat-sen University Cancer Center (Group 1).
In addition, we reviewed the records of 3 patients with
RIBPN who were admitted to our center between January
2001 and December 2007 (Group 2). RIBPN can affect
both sensory and motor function of the ipsilateral armand hand, i.e. paraesthesia, oedema, pain, and dyskinesia.
In present study, RIBPN was graded using a modified late
effects of normal tissue-subjective, objective, management,
and analytic (LENT-SOMA) score [14-16]. The study was
approved by the ethics committee of Sun Yat-Sen Univer-
sity Cancer Center. All patients provided written consent
for storage of their medical information in the hospital
database and for research use of this information.
Contouring of the brachial plexus
In both groups the BP was contoured according to the stan-
dardized Radiation Therapy Oncology Group (RTOG)–
endorsed guidelines delineation [17]: 1) Identify and
contour C5, T1, and T2; 2) Identify and contour the sub-
clavian and axillary neurovascular bundle; 3) Identify and
contour anterior and middle scalene muscles from C5 to
insertion onto the first rib; 4) Contour the brachial plexus
as an organ at risk (OAR) using a 5-mm diameter paint
tool; 5) Start at the neural foramina from C5 to T1; this
should extend from the lateral aspect of the spinal canal
to the small space between the anterior and middle sca-
lene muscles; 6) For computed tomography (CT) slices,
where no neural foramen is present, contour only the
space between the anterior and middle scalene muscles; 7)
Continue to contour the space between the anterior and
middle scalene muscles; eventually the middle scalene will
end in the region of the subclavian neurovascular bundle;
8) Contour the brachial plexus as the posterior aspect of
the neurovascular bundle inferiorly and laterally to 1–2
CT slices below the clavicular head; 9) The first and sec-
ond ribs serve as the medial boundary of the OAR contour
(Figure 1).
Treatment plan
All patients both groups were irradiated to the ISCL area
and chest wall (CW). The total dose was 50 Gy in 25 frac-
tions. The patient had a supine treatment position. All
patients had three-dimensional dose planning (Pinnacle
7.4f ®; Philips Medical Systems, Bothell, WA, USA) based
on CT scanning with a slice thickness of 5 mm. A plan-
ning target volume (PTV) including the chest wall, supra-
clavicular and infraclavicular (SIF) fossa as delineated. A
common isocentre for all fields independent of the tech-
nique was located in the junction between the SIF fields
and CW fields. A high-energy linac with photon beams and
electron beams was used. All treatment plans were indi-
vidually optimized. The ISCL field dose was specified to
cover > 95% PTV with at least 95% of the prescribed dose.
The ISCL was irradiated with 6 MV X-ray and 12–15 MeV
electron beam, and the CW was irradiated with a 6 MV
X-ray tangent field. The axillary and internal mammary
lymph nodes were not irradiated. Thirty-one patients were
redesigned the treatment plan without irradiation to
ISCL to compare the radiation doses to the BP with
Table 1 The correlation of clinical and dosimetric
parameters with RIBPN
Characteristic Group 1 Group 2 p
Age (y) 49 (34–63) 36 (31–43) 0.056
Height (m) 1.58 ± 0.05 1.51 ± 0.03 0.073
Weight (kg) 56.13 ± 7.38 47.60 ± 1.83 0.090
BMI (kg/m2) 22.52 ± 2.44 20.86 ± 0.28 0.259
Number of RLNs (n) 23.42 ± 6.51 34.00 ± 10.15 0.044
Dmean (Gy) 44.39 ± 4.13 47.03 ± 1.54 0.286
Dmax (Gy) 56.16 ± 2.58 59.33 ± 0.83 0.111
V40 (%) 79.90 ± 10.74 87.55 ± 2.91 0.202
V45 (%) 68.22 ± 12.63 76.29 ± 3.85 0.271
V50 (%) 49.25 ± 16.58 58.97 ± 3.41 0.320
V52.5 (%) 28.52 ± 18.98 32.12 ± 3.70 0.740
V55 (%) 6.08 ± 10.36 5.81 ± 1.51 0.963
BMI: body mass index; RLNs: removed lymph nodes.
Vn indicates the volume of the BP receiving n Gy.
Figure 1 Beam eye view (BEV) and cross-sectional diagram of the brachial plexus (PTV marked with blue lines).
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tograms (DVH). The correlation between patient clinical
features and the radiation dose to the BP with irradiation
to the ISCL area and CW was determined. Three patients
with RIBPN after PMRT also were examined with respect
to the radiation dose to the BP and clinical features.
Statistical analysis
SPSS 19.0 software was used for data analysis. The correl-
ation between the radiation dose to the BP and clinical
features was analyzed using Pearson’s correlation coeffi-
cient. The independent effects of the clinical and dosimet-
ric parameters associated with RIBPN development were
determined by univariate and multivariate logistic regres-
sion analysis. Factors with statistically significant differ-
ences in univariate analysis were included in multiple
logistic regression analysis. The correlation between the
radiation dose to the BP and clinical features was analyzed
using Pearson’s correlation coefficient. Radiation doses of
various plans were compared using paired t test. A value
of p < 0.05 was considered to be statistically significant.
Results
The correlation of clinical and dosimetric parameters with
RIBPN
Table 1 shows the correlation of clinical and dosimetric
parameters with RIBPN using univariate logistic regres-
sion analysis. Patients with a higher number of RLNs had
a higher risk of RIBPN (hazard ratio [HR]: 1.189, 95% con-
fidence interval [CI]: 1.005-1.406, p = 0.044). Patients with
younger age (p = 0.056), shorter height (p = 0.073) and
lower weight (p = 0.090) had a borderline significant trend
with RIBPN development. The further multivariate logistic
regression analysis was not performed due to only one fac-
tor had predictive value with RIBPN development.
BP dose, equivalent uniform dose, and body mass index
of Group 1
The median follow-up time of 31 patients was 80.0 months
(range, 74–85 months). The mean dose (Dmean) to the
BP without irradiation to the ISCL area was 0.97 ±0.20 Gy, and the dose to the BP increased significantly
with irradiation to the ISCL area (t = 136.75, p < 0.001)
(Table 1 and Figure 2). In the 3DCRT plans with irradi-
ation to the ISCL area and chest wall, the maximum dose
(Dmax) to the BP was negatively correlated with age
(r = −0.40, p = 0.026), body mass index (BMI) (r = −0.44,
p = 0.014) and body weight (r = −0.450, p = 0.011). There
was no correlation between BP Dmax and height, and
there was no correlation between BP Dmean and age
(r = −0.18, p = 0.340), height (r = −0.01, p = 0.990), BMI
(r = −0.34, p = 0.060), or weight (r = −0.28, p = 0.120).
BP dose and clinical characteristics of patients with RIBPN
(Group 2)
Between January 2001 and December 2007, a total of 629
breast cancer patients whose median follow-up duration
was 63.1 months (range, 6–130 months). The postmastec-
tomy CW and ISCL area received a dose of 50 Gy in 25
fractions with 3DCRT. All patients received 3DCRT after
chemotherapy, and none of these patients received con-
current chemoradiotherapy. Of these patients, 3 (0.48%)
Figure 2 Clinical data and radiation dose to the brachial plexus in group 1 and group 2 patients.
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occurred in a median of 39 months (range, 37–65 months)
after radiotherapy. The time interval between the first ap-
pearance of symptoms and diagnosis was more than
6 months in all patients. Symptoms of the affected limbs
were aggravated in all 3 patients, and progressive neuro-
pathic pain occurred. Two patients had decreased muscle
power of the intrinsic muscles and flexion dysfunction.
Physical examination showed that there were no signifi-
cant differences between the healthy limb and the affected
limb in skin color and temperature. Only enlargement of
the limb circumference because of lymphedema was
noted. Electromyography (EMG) showed injury of the BP
trunk. Tumor factors were excluded by magnetic resonance
imaging (MRI). Symptomatic treatments such as analgesics
and neurotrophic drugs were administered to all 3 patients,
and 2 patients also received physical rehabilitation. AfterTable 2 Characteristics of patients with radiation-induced bra
Characteristic Patient 1 Patie
Tumor location Left breast Left b
Staging of the primary tumor (AJCC 2008) T2N2M0 T1N3
Surgeries MRM and ALND MRM
Chemotherapy 6 courses of DCE 6 cou
Endocrine therapy - TAM
Onset of symptoms after radiotherapy 35 months 27 m
Symptom occurrence to seeking care 7 months 12 m
Initial symptoms Sensory disorders Moto
Overall symptoms Pain, sensory disorders Moto
Localization of injury C5-Th1 C5-7
Severity of injury (LENT-SOMA scale) Grade 2 Grade
Upper-extremity edema Yes No
Time of treatment 27 months 31 m
Treatment outcome Stable Slow
MRM: modified radical mastectomy; ALND: axillary lymph node dissection; DCE: doc
5-fluorouracil; LENT-SOMA: late effects of normal tissue-subjective, objective, managtreatment, 1 patient was stable, and the other 2 patient’s
symptoms worsened. The dose to the BP and clinical
characteristics of the patients with RIBPN are shown in
Tables 1 and 2 and Figure 2.Discussion
Our analyses of the 3DCRT plans of 31 patients who re-
ceived PMRT to the ISCL area and CW showed that the
dose to the BP was related to irradiation to the ISCL
area. This finding is consistent with that of Stanic et al.
[18]. There have been few studies on the occurrence of
RIBPN symptoms, including worsening chronic pain and
decreased sensory and motor function, among the pa-
tients with breast cancer, head and neck cancer, and lung
cancer after irradiation to the BP [10-13,19]. Import-
antly, at present RIBPN is an incurable complication.chial plexus neuropathy
nt 2 Patient 3
reast Right breast
M0 T3N3M0
and ALND MRM and ALND




r deficits Motor deficits






etaxel, cyclophosphomide, epirubicin; CEF: cyclophosphamide, epirubicin,
ement, and analytic.
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RIBPN in the literature. RIBPN incidence is in accord-
ance with the irradiation technique, and ranges from
66% RIBPN with 60 Gy in 5 Gy fractions in the 1960s to
less than 1% with 50 Gy in 2.0 Gy fractions today [19].
In present study, the incidence of RIBPN was 0.48%.
However, a study which 20% patients developed RIBPN
when irradiation to the supraclavicular lymph nodes and
chest wall (breast) using 3DCRT technique with 50 Gy
in 2.0 Gy fractions [11]. Based on the radiation tech-
nique in modern era, the combined treatment-related
factors (surgery in the case of haematoma or chronic
infection and extended axillary lymph node dissection,
et al.) and the patient-related factors (young or ad-
vanced age, obesity, hypersensitive patients, or smoking,
et al.) may affect the risk, severity, and nature of RIBPN
[20]. The follow-up time for different study may also affect
the incidence of RIBPN.
It has been reported that the incidence of RIBPN is
primarily related to the total dose and fractionated dose
to the BP [21-23]. Moreover, Killer et al. reported the in-
cidence of RIBPN was positively correlated with the dose
to the BP [24]. These findings may be related to the fact
that the BP is a serial organ. Therefore, Emami et al.
[25] have suggested that the dose tolerance for a 5% risk
of developing RIBPN at 5 years is 62, 61 and 60 Gy, and
for a 50% risk at 5 years the dose tolerances are 77, 76
and 75 Gy for one-third, two-thirds and the whole organ
respectively. Lundstedt et al. reported that the incidence
of RIBPN is 20% after conventional fractionation radio-
therapy when the prescribed dose to ISCL is 50 Gy [11].
Though the prescribed dose in our patients was 50 Gy,
the BP Dmax was higher than 110% of the prescribed
dose in some cases. Moreover, for patients with lymph
node metastases in the ISCL area, the local dose with
boost could be up to 60–70 Gy, which may lead to an
increased incidence of RIBPN [26]. For these reasons,
we suggest that the BP should be considered as one of
the OAR when the ISCL area is planned to be irradiated.
But we can not come up with a recommendation of the
appropriate dose constraints to brachial plexus due to
limited number of patients. The Danish Breast Cancer
Cooperative Group recommend the maximum dose to
BP should not exceed 54 Gy [27]. In present study, the
Dmax to BP in Group 1 and Group 2 are more than 54 Gy.
A French study suggested that the Dmax to BP should not
exceed 60 Gy, even if possible, 50 Gy [28]. Conventionally,
ISCL fields are matched on to tangential breast fields
using various techniques [29], the difficulties in matching
treatment fields to achieve homogenous dose distribution
may results in overdose to BP. Therefore, it is very difficult
to achieve a dose of less than 50 Gy of BP. Helical
tomotherapy and integrated IMRT treatment plans im-
proved the dose distribution of the supraclavicular regionand showed better dose conformity and uniformity of the
integrated target volume of the chest wall and supraclavi-
cular region without the requirement of field matching
[26,30]. Thus, the new irradiation techniques with brachial
plexus-sparing may be beneficial to the protection of the
brachial plexus.
There have few studies on the relationship between
the dose to the BP and morbidity, disease severity, and
chemotherapy [24]. In addition, unconventional fraction-
ated irradiation is becoming more widely used, which
may potentially lead to an increased incidence of RIBPN
[10,21,31]. Thus, it is necessary to establish risk models
for RIBPN based on DVH or normal tissue complication
probability models in further research.
In present study, the Dmax to BP was not associated
with RIBPN, but patients with a higher number of RLNs
were the independent factor associated with RIBPN devel-
opment. Thus, the dose to the BP should be decreased as
much as possible when the dose to the planned target
volume is satisfied in patients with a higher number of re-
moved lymph nodes. In addition, lymphedema after axil-
lary dissection can cause brachial plexus neuropathy in
breast cancer patients. It was about 13% patients developed
brachial plexus neuropathy after axillary dissection without
regional radiotherapy. Radiotherapy to the supraclavicular
lymph nodes after axillary dissection increases the inci-
dence of brachial plexus neuropathy. When adjusted for
lymphedema the contribution from radiotherapy is no lon-
ger formally statistically significant indicating that there is
also an indirect effect mediated by the lymphedema [11].
Olson et al. [32] and Lundstedt et al. [11] have reported
that the incidence of RIBPN was higher in young patients.
This is consistent with our finding of a negative correlation
between BP Dmax and age. However, it was also reported
that there was no correlation between age and the inci-
dence of RIBPN [23]. In addition, our study showed that
BP Dmax was negatively correlated with BMI and body
weight, which is the same as reported by Klein et al. [33].
These findings indicate that the dose to the BP is relatively
higher in slim patients. This, to a certain degree, explains
why RIBPN is more likely to occur in slim and young pa-
tients. In present study, patients with younger age, shorter
height and lower weight had a borderline significant trend
with RIBPN development. The further studies with a larger
sample size are needed to confirm our study.
Of the 629 patients with irradiation to the ISCL area
and chest wall, only 3 (0.48%) developed RIBPN. The de-
velopment of the RIBPN symptoms in the 3 patients had
a relatively long latent period; thus, a diagnosis of RIBPN
may be delayed because of mile symptoms in the early
stage of the condition. On the other hand, the disease
results in progressive and irreversibility deterioration
and conservative treatment is ineffective. Surgical treat-
ments including BP neurolysis and revascularization by
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not provided satisfactory results [23]. Induced pluripo-
tent stem cell (IPSC) therapy is a new promising tech-
nique that is still in the preclinical testing stage. Because
comprehensive management of breast cancer has re-
sulted in greater long-term survival, greater attention
should be paid to prevent the occurrence of RIBPN.
There are several limitations to this study that should
be considered. First, the study was retrospective, and the
sample size was relatively small. In addition, the follow-
up duration was relatively short, and the number of re-
ported RIBPN cases was small. Therefore, the results
cannot represent the majority of population.
Conclusions
In summary, the incidence of RIBPN was higher in patients
with a higher number of RLNs after PMRT. The dose to
the BP is primarily from irradiation to the ISCL area, and
is higher in slim and young patients. Prevention should be
the main focus of managing RIBPN, especially for slim and
younger patients. Based on the results of this study, we
suggest that the BP should be considered an OAR when
designing a radiotherapy plan for the ISCL area.
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